TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.
TWiV reviews the emergence of remdesivir-resistant SARS-CoV-2 during treatment of a persistently infected immunocompromised patient, and how altered TMPRSS2 utilization by the Omicron variant influences infectivity and fusion.
TWiV explains why hydroxychloroquine failed in humans despite showing antiviral effects in cells, and reviews the published data on the Pfizer/BioNTech mRNA vaccine.
Susan Weiss recalls some of her 40 years of research on coronaviruses, including mouse hepatitis virus, MERS-CoV, and now SARS-CoV-2.
Daniel Griffin provides his weekly update on the COVID-19 clinical situation, followed by our discussion of tests of an inactivated vaccine, results of serological surveys, an inhibitor of the cell protease needed for virus entry, and answers to listener questions.
Vincent, Alan, Rich and Kathy review a protease essential for influenza pathogenesis in mice, and directionality of rhinovirus RNA exit from the capsid.